Loading clinical trials...
Loading clinical trials...
An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination With Low Dose Cytarabine (LDAC) in Adult Patients With Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS)
Conditions
Interventions
Pevonedistat
Cytarabine
Locations
1
United States
University of Miami
Miami, Florida, United States
Start Date
May 21, 2018
Primary Completion Date
June 25, 2021
Completion Date
June 25, 2021
Last Updated
December 28, 2021
NCT03050268
NCT06973668
NCT06656494
NCT05735717
NCT07500441
NCT05756777
Lead Sponsor
Justin Watts, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions